Natera, Inc. (NTRA) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$365.24

From 52W high+0.00%

Volume3.61M

Market cap$53.25B

P/E (TTM)—

P/S (TTM)19.7x

Div yield—

Key dataSep 18, 2026

Open

$365.24

From 52W high

+0.00%

Volume

3.61M

Market cap

$53.25B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−292.5x

P/E (TTM)

—

RSI (14)

69.5

MomentumView details →

1D Return

+0.84%

YTD Return

+57.81%

SummaryUpdated Jun 1, 2026

Natera, Inc. (NASDAQ:NTRA) is a molecular diagnostics company founded in 2003 and headquartered in Austin, Texas. Originally known as Gene Security Network, Inc., the company changed its name to Natera in 2012 and went public in 2015. Natera has evolved from a genetics-focused startup into a leading provider of genetic testing services across three primary healthcare segments: women's health, oncology, and organ health. The company develops and commercializes advanced molecular testing services that analyze DNA to provide critical medical information for patients and healthcare providers worldwide.

Ask drillr about Natera, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−292.5x

EV/Sales

19.4x

P/S (TTM)

19.7x

P/B (TTM)

29.2x

ProfitabilityView details →

Gross Margin

65.30%

Net Margin

−7.11%

EBITDA Margin

−6.62%

ROE (TTM)

−10.56%

ROA (TTM)

−7.24%

Asset Turnover

1.03x

GrowthView details →

Revenue YoY

+37.82%

EPS YoY

+28.80%

FCF YoY

−31.43%

Revenue CAGR 3Y

+41.14%

EPS CAGR 3Y

+0.65%

EBITDA YoY

+15.44%

MomentumView details →

1D Return

+0.84%

YTD Return

+57.81%

1Y Return

+99.62%

RSI (14)

69.5

vs 50D SMA

+18.87%

vs 200D SMA

+50.23%

Capital & dividendView details →

Debt/Equity

0.13x

Current Ratio

3.00x

Quick Ratio

2.85x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.47

EPS Surprise

4.85%

Beats (12Q)

7/12

Next Q EPS Est

−$0.22

Avg Surprise (4Q)

−21.75%

Rev Surprise

13.84%

Financials snapshotView financials →

Revenue (TTM)

2.71B

Net Income (TTM)

−192.35M

Op. CF (TTM)

228.24M

Next earningsNov 5, 2026 →

Latest newsMore news →

Natera CEO and President Steven Leonard Chapman sold 1,698 shares of common stock on Sept. 1, 2026, under a Rule 10b5-1 plan amended in March 2026, per an SEC Form 4 filing.2d ago

Natera presented new data on its Signatera molecular residual disease test, including the largest MRD dataset in lung cancer, at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea.2d ago

Similar companies

Agilent Technologies, Inc.A IQVIA Holdings Inc.IQV Waters CorporationWAT IDEXX Laboratories, Inc.IDXX Hangzhou Tigermed Consulting Co., Ltd.03347.HK Illumina, Inc.ILMN Find similar companies →

Latest newsMore news →

Natera CEO and President Steven Leonard Chapman sold 1,698 shares of common stock on Sept. 1, 2026, under a Rule 10b5-1 plan amended in March 2026, per an SEC Form 4 filing.2d ago Natera presented new data on its Signatera molecular residual disease test, including the largest MRD dataset in lung cancer, at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea.2d ago Natera announced a national partnership with Susan G. Komen to accelerate breast cancer awareness and education, including efforts to increase understanding of minimal residual disease (MRD).23d ago